Cargando…

HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases

HMGB1, a nucleoprotein, is expressed in almost all eukaryotic cells. During cell activation and cell death, HMGB1 can function as an alarm protein (alarmin) or damage-associated molecular pattern (DAMP) and mediate early inflammatory and immune response when it is translocated to the extracellular s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Wenxuan, Zhao, Lei, Sun, Ying, Wang, Xichang, Shi, Xiaoguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478470/ https://www.ncbi.nlm.nih.gov/pubmed/37667233 http://dx.doi.org/10.1186/s10020-023-00717-3

Ejemplares similares

Toll-like receptors in systemic autoimmune disease
por: Marshak-Rothstein, Ann
Publicado: (2006)

Toll-like Receptor 2 in Autoimmune Inflammation
por: Marks, Kathryne E., et al.
Publicado: (2021)

Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease
por: Zhang, Yingchi, et al.
Publicado: (2021)

Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer
por: Muccioli, Maria, et al.
Publicado: (2012)

Toll-like receptor 2: therapeutic target for gastric carcinogenesis
por: McCormack, William, et al.
Publicado: (2012)

Recent clinical trends in Toll‐like receptor targeting therapeutics
por: Anwar, Muhammad Ayaz, et al.
Publicado: (2018)

Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies
por: Farooq, Mariya, et al.
Publicado: (2021)

Toll‐like receptors in pathogenesis of neurodegenerative diseases and their therapeutic potential
por: Dabi, Yosef Tsegaye, et al.
Publicado: (2023)

Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma
por: Xun, Yang, et al.
Publicado: (2021)

HMGB-1 induces c-kit(+) cell microvascular rolling and adhesion via both toll-like receptor-2 and toll-like receptor-4 of endothelial cells
por: Furlani, Dario, et al.
Publicado: (2012)

Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
por: Li, Man, et al.
Publicado: (2018)

Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors
por: Abarca-Merlin, D. M., et al.
Publicado: (2019)

Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems
por: Li, Haixia, et al.
Publicado: (2021)

Therapeutic potential of HMGB1-targeting agents in sepsis
por: Wang, Haichao, et al.
Publicado: (2008)

HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
por: Wang, Yanbin, et al.
Publicado: (2019)

Attenuation of Myocardial Injury by HMGB1 Blockade during Ischemia/Reperfusion Is Toll-Like Receptor 2-Dependent
por: Mersmann, Jan, et al.
Publicado: (2013)

Sulfatide Inhibits HMGB1 Secretion by Hindering Toll-Like Receptor 4 Localization Within Lipid Rafts
por: Kim, Hee Sue, et al.
Publicado: (2020)

Regulation of innate and adaptive immunity and autoimmunity by Toll-like receptor 9
por: Krieg, AM
Publicado: (2004)

Toll-Like Receptor Activation in Immunity vs. Tolerance in Autoimmune Diabetes
por: Gülden, Elke, et al.
Publicado: (2014)

Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus
por: Pradhan, Vandana D., et al.
Publicado: (2012)

The involvement of Toll‐like receptor 9 in the pathogenesis of erosive autoimmune arthritis
por: Fischer, Anita, et al.
Publicado: (2018)

Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
por: Rip, Jasper, et al.
Publicado: (2019)

TNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor Signaling
por: Shamilov, Rambon, et al.
Publicado: (2018)

Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders
por: Ashayeri Ahmadabad, Rezan, et al.
Publicado: (2021)

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease
por: Wu, Linyu, et al.
Publicado: (2022)

Identification of Potential Pathway Mediation Targets in Toll-like Receptor Signaling
por: Li, Fan, et al.
Publicado: (2009)

Toll-Like Receptor Signaling Pathways—Therapeutic Opportunities
por: Zhu, Jiankun, et al.
Publicado: (2010)

Targeting Toll-Like Receptors for Treatment of SLE
por: Horton, Christopher G., et al.
Publicado: (2010)

Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments
por: Duffy, Laura, et al.
Publicado: (2016)

Toll-like receptor 4 inhibition prevents autoimmune diabetes in NOD mice
por: Alibashe-Ahmed, Mohamed, et al.
Publicado: (2019)

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021)

Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application
por: Bai, Ling, et al.
Publicado: (2017)

Counting the Toll of Inflammation on Schizophrenia—A Potential Role for Toll-like Receptors
por: Patlola, Saahithh Redddi, et al.
Publicado: (2023)

Correction: Identification of Potential Pathway Mediation Targets in Toll-like Receptor Signaling
por: Li, Fan, et al.
Publicado: (2009)

Effects of Toll-Like Receptors 3 and 4 in the Osteogenesis of Stem Cells
por: Qi, Chen, et al.
Publicado: (2014)

Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer
por: Yoshida, Tatsuya, et al.
Publicado: (2020)

Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease
por: Aslaksen, Sigrid, et al.
Publicado: (2019)

Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
por: Singh, Harbinder, et al.
Publicado: (2022)

Toll-like Receptors and Thrombopoiesis
por: Tang, Xiaoqin, et al.
Publicado: (2023)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7ks0q9m4ec8dvfm2iki41tobb5